View More Recent Stories

Jul 22, 2025 08:52AM Mizuho Desk Comments on Replimune (REPL)
Jul 22, 2025 08:50AM Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'
Jul 22, 2025 07:03AM Replimune receives FDA rejection letter for melanoma treatment
Jul 15, 2025 02:47PM Replimune (REPL) 11,800 contracts of July 12.50 calls trade, share price up 6.4%
Jul 7, 2025 09:38AM Increasing unusual call option volume: BTBT ACLS CNC SHLS REPL
Jul 7, 2025 06:36AM H.C. Wainwright Reiterates Buy Rating on Replimune Group (REPL)
Jun 25, 2025 07:04AM Cantor Fitzgerald Reiterates Overweight Rating on Replimune Group (REPL)
Jun 20, 2025 06:09AM Cantor Fitzgerald Starts Replimune Group (REPL) at Overweight
Jun 3, 2025 10:07AM JPMorgan Reiterates Overweight Rating on Replimune Group (REPL)
Jun 2, 2025 06:43AM Replimune Group (REPL) PT Raised at Piper Sandler; 'Raising Numbers After Multiple Recent Updates'
May 22, 2025 07:17AM Replimune Group, Inc. (REPL) Misses Q4 EPS by 235c
Feb 13, 2025 06:48AM Replimune Group (REPL) PT Raised to $22 at H.C. Wainwright
Jan 21, 2025 11:00AM Replimune Group (REPL) PT Raised to $27 at BMO Capital
Jan 21, 2025 10:32AM Barclays Reiterates Overweight Rating on Replimune Group (REPL)
Jan 21, 2025 08:05AM Replimune (REPL) Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
Dec 3, 2024 03:59PM Replimune Group (REPL) PT Raised to $19 at Jefferies
Nov 26, 2024 06:05AM Replimune (REPL) Prices Upsized 6.92M Share Offering at $13/sh
Nov 25, 2024 07:10AM Replimune (REPL) Announces $125M Proposed Public Offering
Nov 22, 2024 09:08AM Replimune Group (REPL) PT Raised to $18 at BMO Capital
Nov 21, 2024 04:42PM After-hours movers: Intuit, NetApp, Ross Stores, GAP
Nov 21, 2024 04:06PM Replimune (REPL) Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
Nov 12, 2024 08:08AM Replimune Group, Inc. (REPL) Tops Q2 EPS by 14c
Sep 16, 2024 07:12AM H.C. Wainwright Reiterates Buy Rating on Replimune Group (REPL)
Sep 10, 2024 08:17AM BMO Capital Reiterates Outperform Rating on Replimune Group (REPL)
Sep 10, 2024 06:42AM H.C. Wainwright Reiterates Buy Rating on Replimune Group (REPL)
Sep 9, 2024 09:37AM Roth/MKM Reiterates Buy Rating on Replimune Group (REPL)
Sep 9, 2024 08:01AM Replimune (REPL) Reports Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024
Sep 5, 2024 08:04AM Replimune (REPL): Stockholders Vote to Elect Madhavan Balachandran to Board of Directors
Aug 27, 2024 04:04PM Roth/MKM Starts Replimune Group (REPL) at Buy
Aug 13, 2024 08:01AM Replimune (REPL) Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
Aug 8, 2024 09:27AM Replimune Group, Inc. (REPL) Tops Q1 EPS by 8c
Jun 13, 2024 08:33AM Replimune (REPL) Announces $100 Million Private Placement Financing
View More Recent Stories